Top Markets
Coin of the day
Bright Minds Biosciences Inc. Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc.

DRUG
Classifica tra le azioni #11320
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Prezzo delle azioni
$73.12
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$715.61M
Variazione (1 giorno)
-1.90%
Variazione (1 anno)
88.01%
Paese
US
Scambia Bright Minds Biosciences Inc. (DRUG)

Categoria

Rapporto P/B per Bright Minds Biosciences Inc. (DRUG)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Bright Minds Biosciences Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Bright Minds Biosciences Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH